Strategic partnership Recent collaboration with Coherus BioSciences to conduct a Phase 1 trial of ZM008 in combination with an immune checkpoint inhibitor indicates a clear pathway for co-development, co-commercialization, and expanded access opportunities for early-stage biologics.

Fundraising momentum Series B funding and pre-Series B activity totaling around 7.3 million USD from notable investors signals strengthened financial backing and validation of Zumutor’s platform, presenting an opening to engage strategic investors for future collaborations or licensing deals.

Clinical focus Zealous emphasis on immuno-oncology with ZM008 and ongoing IND activity positions the company as a partner for oncology drug development programs, offering opportunities for CRO/partner services, ancillary studies, and platform-driven dosing or analytics support.

Platform strengths Zumutor highlights glyco-engineering, protein display platforms, and intensive characterization, suggesting sales opportunities around process development, analytical services, and manufacturing optimization for niche biologics.

Global reach potential As the US affiliate of Theramyt Novobiologics with a lean team, there is potential to scale partnerships, licensing, or distribution arrangements in North America and beyond by leveraging existing investor interest and strategic alliances.